{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:28:25Z","timestamp":1793104105416,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.dld.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:58:29Z","timestamp":1612659509000},"page":"691-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know"],"prefix":"10.1016","volume":"53","author":[{"given":"Lucas","family":"Guillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Achit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Ayav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Frimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.01.015_bib0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s12325-016-0393-7","article-title":"Gastroenterologists\u2019 perceptions regarding ulcerative colitis and its management: results from a large-scale survey","volume":"33","author":"Lasch","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ibd.20793","article-title":"Impact of ulcerative colitis from patients\u2019 and physicians\u2019 perspectives: results from the UC: NORMAL survey","volume":"15","author":"Rubin","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0269-2813.2004.01827.x","article-title":"Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"Loftus","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00054725-200011000-00003","article-title":"Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis","volume":"6","author":"Birketvedt","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0009","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bmj.4.5786.518","article-title":"Comparative nephrotoxicity of aspirin and phenacetin derivatives","volume":"4","author":"Calder","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.dld.2021.01.015_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.5793.152","article-title":"Nephrotoxic lesions from 5-aminosalicylic Acid","volume":"1","author":"Calder","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.dld.2021.01.015_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/00365529009091911","article-title":"Mesalazine: an overview of key preclinical studies","volume":"172","author":"Bilyard","year":"1990","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.dld.2021.01.015_bib0012","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1023\/A:1007423911613","article-title":"Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines","volume":"13","author":"Noble","year":"1997","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.dld.2021.01.015_bib0013","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0272-6386(96)90570-3","article-title":"The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations","volume":"28","author":"Bennett","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJM198403013100905","article-title":"Renal syndromes associated with nonsteroidal antiinflammatory drugs","volume":"310","author":"Clive","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.01.015_bib0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/ki.1980.173","article-title":"Mechanisms in the development of analgesic nephropathy","volume":"18","author":"Duggin","year":"1980","journal-title":"Kidney Int"},{"key":"10.1016\/j.dld.2021.01.015_bib0016","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.01.015_bib0017","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000326682","article-title":"Drug-induced nephrotoxicity in inflammatory bowel disease","volume":"119","author":"Oikonomou","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.dld.2021.01.015_bib0018","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ndt\/11.4.614","article-title":"Mesalazine-associated interstitial nephritis","volume":"11","author":"World","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dld.2021.01.015_bib0019","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.301.6755.818-b","article-title":"Nephrotic syndrome associated with sulphasalazine","volume":"301","author":"Barbour","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2021.01.015_bib0020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5414\/CNP61083","article-title":"Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?","volume":"61","author":"Elseviers","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.dld.2021.01.015_bib0022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0023","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gut.35.10.1493","article-title":"Mesalazine induced interstitial nephritis","volume":"35","author":"Thuluvath","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.01.015_bib0024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/ajkd.2001.25216","article-title":"Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid","volume":"38","author":"Haas","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000064461","article-title":"Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"92","author":"Frandsen","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.dld.2021.01.015_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based Consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.01.015_bib0028","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.01.015_bib0029","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.01.015_bib0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.01.015_bib0031","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.01.015_bib0032","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2036.2005.02462.x","article-title":"Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom","volume":"21","author":"Muller","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0033","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2002.01216.x","article-title":"Review article: monitoring for drug side-effects in inflammatory bowel disease","volume":"16","author":"Cunliffe","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0034","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1157\/13127088","article-title":"Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study","volume":"31","author":"Gisbert","year":"2008","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.01.015_bib0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/apt.15408","article-title":"No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study","volume":"50","author":"Jairath","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0036","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cca.2008.05.020","article-title":"Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function","volume":"395","author":"Toffaletti","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dld.2021.01.015_bib0037","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.crohns.2012.08.013","article-title":"5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey","volume":"7","author":"Zallot","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0038","series-title":"Eur J Gastroenterol Hepatol","article-title":"Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with 432 inflammatory bowel disease","author":"Weislinger","year":"2020"},{"key":"10.1016\/j.dld.2021.01.015_bib0039","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00467-004-1411-6","article-title":"Interstitial nephritis from mesalazine: case report and literature review","volume":"19","author":"Arend","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.dld.2021.01.015_bib0040","first-page":"1031","article-title":"Acute interstitial nephritis due to 5-aminosalicylic acid","volume":"143","author":"Mehta","year":"1990","journal-title":"CMAJ"},{"key":"10.1016\/j.dld.2021.01.015_bib0041","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/12.9.1839","article-title":"5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?","volume":"12","author":"De Broe","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dld.2021.01.015_bib0042","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2021.01.015_bib0043","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/gast.2002.36613","article-title":"Primary chronic interstitial nephritis in Crohn's disease","volume":"123","author":"Izzedine","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.01.015_bib0044","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ibd.21468","article-title":"Renal manifestations and complications of inflammatory bowel disease","volume":"17","author":"Oikonomou","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nephro.2018.07.406","article-title":"Tubulointerstitiel nephritis and Crohn's disease, nephrotoxicity or extraintestinal manifestation of Crohn's disease? About a case","volume":"15","author":"Treffel","year":"2019","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0046","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2036.2001.00940.x","article-title":"Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use","volume":"15","author":"Herrlinger","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0047","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/gut.33.10.1348","article-title":"Tests of renal function in patients with quiescent colitis: effects of drug treatment","volume":"33","author":"Riley","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.01.015_bib0048","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/gut.35.11.1599","article-title":"Microalbuminuria in inflammatory bowel disease","volume":"35","author":"Mahmud","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.01.015_bib0049","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/gut.38.1.99","article-title":"Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease","volume":"38","author":"Mahmud","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.01.015_bib0050","first-page":"461","article-title":"Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease","volume":"8","author":"Kreisel","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.01.015_bib0051","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1365-2036.2001.01041.x","article-title":"Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy","volume":"15","author":"Fraser","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0052","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3748\/wjg.v12.i5.739","article-title":"Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?","volume":"12","author":"Poulou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.01.015_bib0053","first-page":"11","article-title":"Diagnosis and management of nephrotic syndrome","volume":"261","author":"McCloskey","year":"2017","journal-title":"Practitioner"},{"key":"10.1016\/j.dld.2021.01.015_bib0054","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semnephrol.2016.05.003","article-title":"Measuring and assessing kidney function","volume":"36","author":"Vart","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.dld.2021.01.015_bib0055","first-page":"S14","article-title":"The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity","volume":"38","author":"Price","year":"1992","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.dld.2021.01.015_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0272-6386(89)80115-5","article-title":"New parameters to monitor the progression of diabetic nephropathy","volume":"13","author":"Di Mario","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0057","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/15.4.498","article-title":"Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity","volume":"15","author":"Monteleone","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dld.2021.01.015_bib0058","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00384-002-0467-7","article-title":"No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases","volume":"18","author":"Dehmer","year":"2003","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0059","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/2009\/501345","article-title":"Renal effects of long-term treatment with 5-aminosalicylic acid","volume":"23","author":"Patel","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.dld.2021.01.015_bib0060","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.MIB.0000185402.65288.19","article-title":"5-Aminosalicylates and effects on renal function in patients with Crohn's disease","volume":"11","author":"de Jong","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0061","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000469669","article-title":"Serum creatinine: not so simple!","volume":"136","author":"Delanaye","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.dld.2021.01.015_bib0062","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.729","article-title":"Assessment of glomerular filtration rate in health and disease: a state of the art review","volume":"102","author":"Levey","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0063","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","article-title":"Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations","volume":"54","author":"Stevens","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0064","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2036.2005.02584.x","article-title":"5-aminosalicylates in inflammatory bowel disease and chronic renal failure","volume":"22","author":"Tekin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.01.015_bib0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.01.015_bib0066","unstructured":"GETAID. D\u00e9riv\u00e9s aminosalicyl\u00e9s: rowasa\u00ae, Fivasa\u00ae, Pentasa\u00ae, Dipentum\u00ae, Salazopyrine\u00ae, Quadrasa\u00ae. Accessed August 2020. https:\/\/www.getaid.org\/fiches-medicament\/les-derives-aminosalicyles-rowasa-fivasa-pentasa-dipentum-salazopyrine-quadrasa"},{"key":"10.1016\/j.dld.2021.01.015_bib0067","unstructured":"Food and Drug Administration. Mesalamine prescribing information as of 05\/2010. Accessed August 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019651s023lbl.pdf"},{"key":"10.1016\/j.dld.2021.01.015_bib0068","unstructured":"Food and Drug Administration. Mesalamine prescribing information as of 07\/2019. Accessed August 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020049s032lbl.pdf"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:16:10Z","timestamp":1761624970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1590865821000219"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.01.015","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}